MEF2C and breast carcinoma: IL-4 (Interleukin 4)-activated TAMs release exosomal miR-223, which favored invasion and aggressiveness in breast cancer cells by the activation of the Mef2c-βcatenin pathway (Myocyte enhancer factor 2c-βcatenin) [180].